title: [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of nateglinide, a new antidiabetic agent, in the treatment of type 2 diabetes.
  
  
  METHODS
  A total of 219 treatment-naïve patients with type 2 diabetes from 6 centers were enrolled in this study and blindly divided into nateglinide group (n = 105) and repaglinide group (n = 114). In all patients, the disease was confirmed for at least three months. The whole observation lasted for 12 weeks. The efficacy indicators measured include glycohemoglobin A1c (HbA1c), fasting blood glucose, and 2 hours postprandial blood glucose, and the safety parameters measured included renal and hepatic function, serum lipids, and blood and urea profiles.
  
  
  RESULTS
  Similar decreases in fasting blood glucose, 2 hours postprandial blood glucose, and HbA1 c were found in both nateglinide group and repaglinide group without significant differences. No severe adverse events were noted. The hypoglycemia event reports were not significantly different between these two groups.
  
  
  CONCLUSIONS
  Nateglinide is an effective and safe drug in treating type 2 diabetes.
authors.affiliation: Department of Endocrinology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China. liyuxiu@hotmail.com
authors.forename: Yu-Xiu
authors.initials: YX
authors.lastname: Li
authors.forename: Guo-Xian
authors.initials: GX
authors.lastname: Ding
authors.forename: Qi-Fu
authors.initials: QF
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Chen
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Hu
authors.forename: Qiu-He
authors.initials: QH
authors.lastname: Ji
authors.forename: Shou-Jun
authors.initials: SJ
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Guo
authors.forename: Rong
authors.initials: R
authors.lastname: Luo
authors.forename: Wei-Kai
authors.initials: WK
authors.lastname: Hou
authors.forename: Pu-Neng
authors.initials: PN
authors.lastname: Wang
authors.forename: Nan-Yan
authors.initials: NY
authors.lastname: Zhang
authors.forename: Ya-Ping
authors.initials: YP
authors.lastname: Zhang
authors.forename: Heng
authors.initials: H
authors.lastname: Wang
mesh_terms: D001786:Blood Glucose / Q000187:drug effects; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077715:Nateglinide; D010649:Phenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D000077715:Nateglinide; D010649:Phenylalanine